



Reg. Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai - 400053
Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com
CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

February 14, 2020

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : 531099
Sub : Outcome of Board Meeting

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Friday, February 14, 2020, has, inter alia, considered and approved the following:

1. Unaudited Standalone Financial Results for the quarter ended December 31, 2019 along with the Limited Review Report thereon;

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For Rubra Medicaments Limited

A handwritten signature in blue ink, appearing to read "Abha Kapoor", with a horizontal line underneath it.

Abha Kapoor
Director (Finance) and CFO
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended December 31, 2019

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		31-Dec-2019	30-Sep-2019	31-Dec-2018	31-Dec-2019	31-Dec-2018	31-Mar-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	12.50	14.00	10.94	35.76	29.12	59.12
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
III	Total Income (I + II)	12.50	14.00	10.94	35.76	29.12	59.12
IV	Expenses:						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	4.68	10.00	10.77	14.68	28.77	32.75
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	2.27	2.41	1.38	11.23	5.21	20.80
	Finance Costs	0.01	0.02	0.02	0.12	0.03	0.04
	Depreciation & amortisation expense	0.04	0.04	0.01	0.13	0.03	0.04
	Other Expenses	3.66	0.75	6.06	5.83	9.40	23.74
	Total Expenses (IV)	10.66	13.22	18.24	31.99	43.44	77.37
	Profit / (loss) before exceptional items and tax (III-IV)	1.84	0.78	-7.30	3.77	-14.32	-18.25
V	Exceptional Items	0.00	0.00	0.00	0.00	0.00	17.11
VI	Profit / (loss) before tax (V-VI)	1.84	0.78	-7.30	3.77	-14.32	-1.14
VIII	Tax Expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Profit (Loss) for the period from continuing operations (VII-VIII)	1.84	0.78	-7.30	3.77	-14.32	-1.14
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit / (Loss) for the period (IX+XII)	1.84	0.78	-7.30	3.77	-14.32	-1.14
XIV	Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	1.84	0.78	-7.30	3.77	-14.32	-1.14
XVI	Earnings per equity share (for continuing operation): (1) Basic (2) Diluted	0.03 0.03	0.01 0.01	0.00 0.00	0.07 0.07	0.00 0.00	0.00 0.00
XVII	Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
XVIII	Earnings per equity share (for discontinued & continuing operation): (1) Basic (2) Diluted	0.03 0.03	0.01 0.01	0.00 0.00	0.07 0.07	0.00 0.00	0.00 0.00
	NOTES:						
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
2	The Segment - wise details are not applicable to the Company as the Company has no segments.						
3	The result is provisional and unaudited and subject to change, regrouping and restatement.						

Place: Mumbai
Date:- February 14, 2020

For Rubra Medicaments Limited


Abha Kapoor
 Director (Finance) & CFO
 DIN: 02799429

DD & COMPANY

CHARTERED ACCOUNTANTS

705, MORYA BLUEMOON, NEAR MONIGINIS CAKE FACTORY, OPP CITI MALL,
LINK ROAD, ANDHERI WEST, MUMBAI - 400053 CONTACT NO: 9820700430


**The Limited Review Report for listed entities other than banks and insurance companies -
unaudited standalone quarterly and year to date results**

To
The Board of Directors
Rubra Medicaments Limited
Mumbai

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the period ended December 31, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Partner
Membership No: 045393

Place: Mumbai
Date: February 14, 2020